Regional disparities in breast cancer healthcare in Japan: REAL-BC study.

IF 2.9
Breast cancer (Tokyo, Japan) Pub Date : 2025-09-01 Epub Date: 2025-08-02 DOI:10.1007/s12282-025-01739-x
Hiroshi Kitagawa, Kazuki Fukuzawa, Masaki Tanaka
{"title":"Regional disparities in breast cancer healthcare in Japan: REAL-BC study.","authors":"Hiroshi Kitagawa, Kazuki Fukuzawa, Masaki Tanaka","doi":"10.1007/s12282-025-01739-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Since 2007, the Basic Plans for Promoting Cancer Control (BPPCCs) have sought to enhance cancer care at designated cancer care hospitals (DCCHs) and implement population (PBCR)- and hospital (HBCR)-based cancer registries, among other activities. However, the impact of the BPPCCs on breast cancer care in Japan remains uncertain. This study sought to reveal the reality of regional disparities in the proportion of breast cancer patients' initial visits to DCCHs and the functionality of breast cancer in DCCHs.</p><p><strong>Methods: </strong>We obtained data from the PBCR and HBCR in Japan, as well as administrative healthcare claims data (JMDC claims data), and data published by clinical societies in Japan for the period 2018 to 2021. We conducted descriptive analyses to determine the proportions of patients who received initial treatment for breast cancer at a DCCH. We also examined the quality of care in terms of staffing and functions.</p><p><strong>Results: </strong>In 2020, out of 79,062 breast cancer patients registered in the HBCR, 57.7% started initial treatment at a DCCH (range across 47 prefectures: 15.5%-89.8%) in Japan. The proportion of patients who visited a DCCH for initial treatment increased from 53.8% (2018) to 57.7% (2020). The median proportion of DCCHs certified by the Japanese Breast Cancer Society (JBCS) among the 47 prefectures was 62.50% (range: 16.7%-100.0%). The median number of patients per JBCS-certified specialist was 77.40 (range: 37.6-142.0). The proportions of DCCHs with claims for breast cancer-related service fees were 15.2% (range: 0.0%-50.0%) for cancer genome profiling tests, 62.0% (range: 0.0%-100.0%) for cancer BRCA1/2 genetic tests, and 92.8% (range: 60.0%-100.0%) for patient support system enhancement.</p><p><strong>Conclusion: </strong>We found regional disparities in the initial treatment and medical services for breast cancer care in Japan. The findings uncover opportunities to enhance the treatment of breast cancer in Japan. We anticipate that our data will be utilized as a valuable resource and as a key input for informing policy development tailored to the specific characteristics of the region and for designing programs to address the different needs of each prefecture.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"1102-1114"},"PeriodicalIF":2.9000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12394363/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast cancer (Tokyo, Japan)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12282-025-01739-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/2 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Since 2007, the Basic Plans for Promoting Cancer Control (BPPCCs) have sought to enhance cancer care at designated cancer care hospitals (DCCHs) and implement population (PBCR)- and hospital (HBCR)-based cancer registries, among other activities. However, the impact of the BPPCCs on breast cancer care in Japan remains uncertain. This study sought to reveal the reality of regional disparities in the proportion of breast cancer patients' initial visits to DCCHs and the functionality of breast cancer in DCCHs.

Methods: We obtained data from the PBCR and HBCR in Japan, as well as administrative healthcare claims data (JMDC claims data), and data published by clinical societies in Japan for the period 2018 to 2021. We conducted descriptive analyses to determine the proportions of patients who received initial treatment for breast cancer at a DCCH. We also examined the quality of care in terms of staffing and functions.

Results: In 2020, out of 79,062 breast cancer patients registered in the HBCR, 57.7% started initial treatment at a DCCH (range across 47 prefectures: 15.5%-89.8%) in Japan. The proportion of patients who visited a DCCH for initial treatment increased from 53.8% (2018) to 57.7% (2020). The median proportion of DCCHs certified by the Japanese Breast Cancer Society (JBCS) among the 47 prefectures was 62.50% (range: 16.7%-100.0%). The median number of patients per JBCS-certified specialist was 77.40 (range: 37.6-142.0). The proportions of DCCHs with claims for breast cancer-related service fees were 15.2% (range: 0.0%-50.0%) for cancer genome profiling tests, 62.0% (range: 0.0%-100.0%) for cancer BRCA1/2 genetic tests, and 92.8% (range: 60.0%-100.0%) for patient support system enhancement.

Conclusion: We found regional disparities in the initial treatment and medical services for breast cancer care in Japan. The findings uncover opportunities to enhance the treatment of breast cancer in Japan. We anticipate that our data will be utilized as a valuable resource and as a key input for informing policy development tailored to the specific characteristics of the region and for designing programs to address the different needs of each prefecture.

Abstract Image

Abstract Image

Abstract Image

日本乳腺癌保健的地区差异:REAL-BC研究
背景:自2007年以来,促进癌症控制的基本计划(BPPCCs)一直在寻求加强指定癌症护理医院(DCCHs)的癌症护理,并实施基于人口(PBCR)和医院(HBCR)的癌症登记,以及其他活动。然而,bppcc对日本乳腺癌治疗的影响仍不确定。本研究旨在揭示乳腺癌患者首次就诊DCCHs比例的地区差异,以及乳腺癌在DCCHs中的功能。方法:我们获得了日本PBCR和HBCR的数据,以及行政医疗索赔数据(JMDC索赔数据),以及日本临床学会公布的2018年至2021年的数据。我们进行了描述性分析,以确定在DCCH接受乳腺癌初始治疗的患者比例。我们还从人员配备和职能方面考察了护理质量。结果:2020年,在HBCR中登记的79062名乳腺癌患者中,57.7%的患者在日本的DCCH开始了初始治疗(涵盖47个县:15.5%-89.8%)。前往DCCH进行初始治疗的患者比例从2018年的53.8%增加到2020年的57.7%。在47个县中,经日本乳腺癌协会(JBCS)认证的DCCHs比例中位数为62.50%(范围:16.7%-100.0%)。每位jbcs认证专家的患者中位数为77.40(范围:37.6-142.0)。要求乳腺癌相关服务费用的DCCHs比例为癌症基因组谱检测15.2%(范围:0.0%-50.0%),癌症BRCA1/2基因检测62.0%(范围:0.0%-100.0%),患者支持系统增强92.8%(范围:60.0%-100.0%)。结论:我们发现日本乳腺癌的初始治疗和医疗服务存在地区差异。这些发现揭示了在日本加强乳腺癌治疗的机会。我们预计,我们的数据将被用作一种宝贵的资源,并作为根据该地区的具体特点制定政策的关键输入,并用于设计满足每个州不同需求的方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信